Sexually Transmitted Diseases

Even as new treatments for the virus become available, access may be an issue thanks to budget re-shuffling in Washington.

As millennials communicate extensively by text, investigators designed a study to improve rates of retention and medication adherence in young men who have sex with men.

Douglas Krakower, MD, explains how predictive models can be used to identify patients that are at a higher risk for HIV and could benefit from learning about PrEP.

Eric Daar, MD, discusses the obstacles associated with new research and technology in the pursuit of finding a cure for HIV.

HIV-specific ex-vivo expanded T cell therapy appears to be safe and well tolerated in people with HIV taking antiretroviral therapy who are virally suppressed.

The current CDC recommended therapy for the treatment of uncomplicated gonorrhea remains the dual combination therapy of 250 mg ceftriaxone delivered intramuscularly and 1 g of azithromycin taken orally.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

When it comes to HPV infection in men who have sex with men, the type of virus they contract has real implications for their future cancer risk.

The US Preventative Services Task Force recommends early screening for syphilis in pregnant women and a literature review has reinforced the recommendations.

Local officials tout benefits of needle exchange, testing programs at reducing risk.

An international literature review indicates that 78% of children with multidrug-resistant tuberculosis were successfully treated with second-line treatment.

In a new study, investigators found that providing guidance and advice in people who inject drugs increased use of antiretroviral medication use by 30%.

Study results suggest that treatment with the anti-inflammatory steroid dexamethasone is associated with slowed clearance of fungal infections in HIV-associated cryptococcal meningitis.

Results of the 2016 European Gonococcal Antimicrobial Surveillance Program report a steady rise in drug resistant-gonorrhea infections.

A treatment comprised of DOR/3TC/TDF was non-superior to EFV/FTC/TDF for primary efficacy but resulted in fewer adverse events.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Colleen Kelley, MD, discusses the importance of keeping all populations on the HIV care continuum, especially those who are at a disadvantage.

Strands of hair have several advantages over plasma samples in revealing whether a person with HIV is adhering to a medication regimen.

Investigators find that only 48% of surveyed health care providers had ever prescribed PrEP.

Although the incidence of Chlamydia trachomatis infections remains high among young women (ages 14-24), new data indicate that prevalence of the sexually-transmitted infection is decreasing.

Eric Daar, MD, explains how gene editing therapy can be used to move the HIV cure agenda forward.

A new study has uncovered how cytomegalovirus can bypass the body’s defense mechanisms that prevent viral infections.

Study results indicate that patients with HIV are willing to wait at least 19 hours or travel up to 28 miles to see a “nice” provider.

The FDA has approved 2 new treatments for HIV: a once-daily fixed-dose combination tablet of doravirine, lamivudine, and tenofovir disoproxil fumarate; and doravirine, a new NNRTI to be administered in combination with other antiretroviral medicines.

A new analysis from the CDC shows steep and sustained increases in STDs in recent years.

Two public health experts discuss the recent rapid increase in incidence of infectious diseases that has been linked with injection drug use.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Colleen Kelley, MD, the biggest barriers to HIV prevention methods and how to overcome them.

Closing treatment gaps is critical to ending the HIV epidemic in the United States.

A new study reveals that the quadrivalent HPV catch-up vaccine was most effective against cancer risk in women who received the first dose between the ages of 14 and 20 years.